IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

A REPORT ON DIAGNOSIS AND TREATMENT OF ERDHEIM-CHESTER DISEASE (ECD)

Name of Authors-
(*Mehak, Taruna Sharma, Kiriti devi, Payal, Siya)
1. Research scholar at Dreamz College of Pharmacy, Distt. Mandi (H.P.)-175036
2. Assistant Professor at Dreamz College of Pharmacy, Distt. Mandi (H.P.)-175036

Abstract

Erdheim-Chester disease (ECD) is a rare, systemic, and progressive condition marked by the spread of organs by foamy histiocytes (irregular macrophage-like cells) and ongoing inflammation. It mainly impacts adults, with a higher prevalence among middle-aged males. The disease is frequently linked to the BRAF V600E mutation, which disrupts the MAPK/ERK signaling pathway, encouraging the growth of histiocytes. This mutation indicates a cancerous aspect in how the disease develops. Symptoms vary widely and can affect several organ systems, such as the heart, kidneys, lungs, and brain. Typical symptoms include bone discomfort, problems with hormone production, and eye lumps. The disease often leads to the gradual failure of organs and significant health issues. To diagnose ECD, histopathology and genetic tests are used, with the BRAF V600E mutation being a crucial indicator. Treatment choices are scarce but may involve specific drugs (like BRAF inhibitors) and treatments that suppress the immune system. Despite progress in understanding the genetic and molecular aspects of ECD, its exact cause is still unknown, and more research is necessary to identify possible environmental factors and improve treatment approaches. ECD is a rare but critical condition to consider in patients with widespread organ involvement and unexplained long-term symptoms.

Keywords: - eye lumps, BRAF inhibitors, ECD, cancerous

1. Introduction

1.1 Erdheim-Chester Disease (ECD)

Erdheim-Chester disease (ECD) is a uncommon form of non-Langerhans cell histiocytosis (LCH). It was initially identified as "lipoid granulomatosis" by Jakob Erdheim and William Chester in 1930, and subsequently honored with its name. Although it's a rare condition, there has been a notable rise in its occurrence in recent years, likely

due to greater recognition of the disease, with over 1500 cases documented globally.One of the key features of ECD is the presence of foamy CD68+ and CD1a– histiocytes in affected tissues. It typically affects multiple systems in the body, including the skeletal, cardiovascular, urologic, renal, retroperitoneal, pulmonary, endocrine, cutaneous, and nervous systems, leading to a wide range of symptoms that depend on which systems are involved. The disease is thought to arise from genetic mutations in the MAPK pathway, such as BRAF V600E and MAP2K1 mutations. Diagnosing ECD involves a combination of clinical, radiological, histopathological, and molecular tests. Identifying these genetic mutations has greatly improved treatment options, leading to more effective and targeted therapies, such as BRAF and MEK inhibitors [1].

1.2 Sign & Symptom of Erdheim-Chester Disease (ECD)

Erdheim-Chester disease (ECD) is a rare blood disorder that can cause a wide range of symptoms, including:

- **Skin:** Soft, fatty, yellow bumps or rash on the skin or eyelids
- **Bones:** Bone pain, especially in the upper arms and lower legs
- **Eyes:** Pain and redness in the eyes, bulging eyes, or rapid, involuntary eye movement
- **Nervous system:** Headaches, seizures, cognitive impairment, or problems with movement or sensation
- **Heart or lungs:** Shortness of breath, especially with exercise, or heart failure
- **Kidneys:** Kidney swelling, kidney atrophy, or renal failure
- **Hormones:** Diabetes insipidus, which causes excessive thirst and urination
- **Other:** Fever, night sweats, fatigue, weakness, and weight loss [2].

1.3 Etiology of ECD

The cause of Erdheim-Chester disease (ECD) remains largely unknown, but a crucial element appears to be the BRAF V600E mutation found in a large portion of patients, leading to the overgrowth of histiocytes through the MAPK pathway. This genetic alteration indicates a malignant aspect in how the disease develops. Moreover, immunological dysfunction and ongoing inflammation are thought to play a part in the buildup of histiocytes. While the impact of environmental triggers and viral infections on the disease's initiation is not definitively known, they might play a role. ECD usually occurs randomly, without a clear pattern of inheritance within families [3].

1.4 Epidemiology of ECD

Men are more likely to have ECD (at least 60% of cases). According to the cases that have been documented, the diagnosis often happens between the ages of 40 and 70, with a mean age of 55. According to estimates, approximately 40% of cases with ECD contain pericardial involvement. Nine (39%) of the 23 ECD patients with

cardiac magnetic resonance imaging (MRI) had pericardial involvement, two (9%) had tamponade, and three (13%) required pericardial drainage. Five (14%) and nine (24%) of the 37 patients in another research had pericardial thickness on cardiac MRI or computed tomography (CT), and one (3%) of them had constriction and another (3%) had delayed enhancement on MRI, indicating continued pericardial Inflammation [4].

1.5Pathophysiology of ECD

Erdheim-Chester Disease (ECD) is a rare systemic condition characterized by the clonal proliferation of non-Langerhans histiocytes (macrophage-like cells) in multiple organs. A significant proportion of cases harbor the BRAF V600E mutation, leading to activation of the MAPK/ERK pathway, promoting histiocytic proliferation and survival [5].This proliferation results in infiltration of tissues, including the skin, bones, heart, lungs, and central nervous system. Key features include vascular involvement, causing thickening of vessel walls, and fibrosis driven by dysregulated cytokine production (e.g., IL-6, TNF-alpha). Infiltrating histiocytes release pro-inflammatory cytokines and growth factors, contributing to organ damage and fibrosis. Clinical manifestations are variable but often include bone pain, cardiovascular complications, pulmonary fibrosis, neurological deficits, and skin lesions like xanthomas. The disease leads to progressive organ dysfunction and significant morbidity [6].

1.6Pathogenesis of Erdheim-Chester Disease

Although the pathophysiology of ECD is still unclear, there have been positive developments in recent years. The recruitment and activation of histiocytes into ECD lesions appears to be caused by a local and systemic pro-inflammatory cytokine–chemokine network, as our group. Elevated levels of interleukin (IL)-12, monocyte chemotactic protein-1, and interferon (IFN)-α are indicative of a distinct inflammatory cytokine signature of ECD [7].

1.7Risk Factors ofErdheim Chester Disease(ECD)

- **Age:** Individuals over 60 have a higher risk of dying from ECD.
- **Organ involvement:** When the disease affects the skeletal, central neurological, or digestive systems, the risk of dying from ECD increases [8].
- **C-reactive protein (CRP) level:** A worse prognosis is linked to a higher C-reactive protein (CRP) level at the beginning of the illness.
- **BRAF gene mutation:** The BRAF gene, which encourages unchecked histiocyte proliferation, is mutated in almost half of individuals with ECD.
- **Sex:** Compared to women, men are somewhat more likely to have ECD.
- **Time to diagnosis:** Although it has been shorter recently, the period of time between the beginning of symptoms and a diagnosis can still be anywhere from a few months to 25 years [9].

2. Diagnosis of ECD

- Since the most prevalent clinical indications (such as skeletal, constitutional, or even neurological symptoms) typically lack sufficient specificity, diagnosing ECD can be difficult. Finding abnormal histiocytes in the right clinical and radiological setting leads to an accurate diagnosis. In actuality, imaging results can be a useful tool. Specifically, the most indicative and specific imaging results include[10].



Fig 2.1 Photograph of skin lesions in a patient with Erdheim-Chester disease showing yellow plaques in the eyelids suggestive of xanthelasmas (a) and confluent, yellow-brown papules in the armpits (b) and antecubital fossa (c)

- **Radiographic**

  Clinical & radiological features of Erdheim Chester Disease in Fig 2.2 [11].



- Most often, histological analysis is used to diagnose ECD. Polymorphic granulomas infiltrated with foamy histiocytes that are both CD68-positive and CD1a-negative, together with fibrosis or

xanthogranulomatosis, are the usual pattern. The diagnosis of ECD requires a histological biopsy; an ultrasound-guided biopsy of the perirenal infiltrate, which is seen in about two thirds of patients, is a preferred method [12].

3. Treatment of Erdheim Chester Disease

Prior to 2005, a small number of case reports detailed several treatment regimens, such as double-autologous haematopoietic stem cell transplantation, cytotoxic drugs, vinca alkaloids (similar to LCH treatment), and steroids. Stem cell transplantation has been dropped for this indication due to recent developments in targeted treatments. Although it has been demonstrated that IFN-α-based regimens increase survival, the most encouraging developments since 2012 have been the efficacy of BRAF and MEK inhibitors. Treatment with IFN-α must be long-term and has several side effects, including fatigue and depression, which affect half of patients [13].

There are currently no randomised controlled studies available, despite the fact that numerous therapy options have been investigated thus far for ECD. The initial approaches that were suggested were steroids, cytotoxic medications (such vinca alkaloids, anthracyclines, and cyclophosphamide), and autologous haematopoietic stem cell transplantation; nevertheless, their clinical effectiveness was limited. Surgical debulking may also be beneficial for certain patients [6].

Biopsy examination and analysis of mTOR pathway activation

A pathologist with experience in soft-tissue tumours (D.C.) centrally examined tissue specimens; routine stainings and immunohistochemistry analysis of CD68 and CD1a expression were carried out. Based on the available samples, the BRAFV600E mutation was evaluated. The Blood website's supplementary Methods section provides information on BRAFV600E testing as well as histology and immunohistochemical investigations. We also looked for recurrent mutations in the NRAS, KRAS, and PIK3CA genes where there was enough biopsy tissue available (supplemental Methods) [14].

4.Result & discussion

A rare systemic disorder called Erdheim-Chester Disease (ECD) is typified by the invasion of foamy histiocytes into several organs. Bone pain, skin lesions, cardiovascular, neurological, and renal involvement are examples of clinical symptoms. BRAF V600E mutations are common, according to recent research, and provide a target for BRAF inhibitor therapy. Treatment is made more difficult by the disease's diverse nature, even with breakthroughs in our understanding of its genetic underpinnings. Although results vary, corticosteroids, chemotherapy, and targeted treatments are frequently used in management. Improving prognosis requires early diagnosis and individualised treatment. To improve treatment approaches and understand the pathogenesis of the condition, ongoing research is essential.

5. CONCLUSION

Because of its uncommon frequency and diverse clinical presentations, Erdheim-Chester Disease (ECD) is difficult to diagnose. Clinical suspicion, imaging tests (such CT or MRI), biopsy demonstrating histiocytic infiltration, and genetic testing for BRAF mutations—especially the V600E mutant, which is crucial to the

pathophysiology of the disease—are usually needed. Because the condition is diverse, treatment approaches are changing yet still customised. Corticosteroids and chemotherapy are frequently used as first-line treatments, however they particularly in individuals who have the BRAF V600E mutation. Nonetheless, controlling multi-organ participation continues to be a major issue, and the overall response may vary. Improving patient outcomes requires continued investigation into the molecular underpinnings of ECD and the creation of more targeted treatment alternatives. Optimising care and prognosis requires early diagnosis and a comprehensive approach to therapy. might not be enough for every patient. Targeted treatments have shown potential, especially BRAF inhibitors.

6. References

1. Aggarwal A, Taychert M, Hasanin L, Doll D, Basuino MG, Hasanein H. Erdheim-Chester Disease: A Case Report of BRAF V600E-Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review. Oncology (Williston Park). 2023 Jul 21;37(7):298-302. doi: 10.46883/2023.25921001. PMID: 37499251.
2. Cives M, Simone V, Rizzo FM, Dicuonzo F, Lacalamita MC, Ingravallo G, Silvestris F, Dammacco F. Erdheim–Chester disease: a systematic review. Critical reviews in oncology/hematology. 2015 Jul 1;95(1):1-1.
3. Adawi M, Bisharat B, Bowirrat A. Erdheim–Chester disease (ECD): Case report, clinical and basic investigations, and review of literature. Medicine. 2016 Oct 1;95(42):e5167.
4. Chahine J, Alzubi J, Alnajjar H, Ramchand J, Chetrit M, Klein AL. Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis. Curr Cardiol Rep. 2020 Jun 30;22(8):75. doi: 10.1007/s11886-020-01307-z. PMID: 32607694.
5. Ben-Yaakov G, Munteanu D, Sztarkier I, Fich A, Schwartz D. Erdheim chester-A rare disease with unique endoscopic features. World Journal of Gastroenterology: WJG. 2014 Jul 7;20(25):8309.
6. Nash M, Rafay MF. Craniocervical arterial dissection in children: pathophysiology and management. Pediatric Neurology. 2019 Jun 1;95:9-18.
7. Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-chester disease. European journal of internal medicine. 2015 May 1;26(4):223-9.
8. Cohen-Aubart F, Emile JF, Carrat F, Helias-Rodzewicz Z, Taly V, Charlotte F, Cluzel P, Donadieu J, Idbaih A, Barete S, Amoura Z. Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort. American journal of hematology. 2018 May;93(5):E114-7.
9. Boyd LC, O'Brien KJ, Ozkaya N, Lehky T, Meoded A, Gochuico BR, Hannah-Shmouni F, Nath A, Toro C, Gahl WA, Estrada-Veras JI. Neurological manifestations of Erdheim–Chester disease. Annals of clinical and translational neurology. 2020 Apr;7(4):497-506.
10. Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM. Erdheim-Chester disease: consensus

recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood, The Journal of the American Society of Hematology. 2020 May 28;135(22):1929-45.

11. Aswani Y, Patel A, Zhan X, Ansari S, Marcelino LG, Aswani N, Patel DD, Kandemirli S, Averill S, Bhatt S. Imaging in Erdheim-Chester Disease. Radiographics. 2024 Sep;44(9):e240011. doi: 10.1148/rg.240011. PMID: 39172709.
12. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, Amoura Z. Erdheim–Chester disease. Current rheumatology reports. 2014 Apr;16:1-8.
13. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile JF, Amoura Z. Erdheim–Chester disease. Current rheumatology reports. 2014 Apr;16:1-8.
14. Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G, Baldari G, De Filippo M, Ferretti S, Moroni G, Foti R. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood, The Journal of the American Society of Hematology. 2015 Sep 3;126(10):1163-71.